Comparison of the Nephrotoxicity of Netilmicin and

Similar documents
VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill

Persistent in Kidneys

Aspects of the Chronic Toxicity of Gentamicin Sulfate in Cats

Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci

GENTAMICIN: ACTIVITY IN VITRO AGAINST GRAMNEGATIVE ORGANISMS AND CLINICAL EXPERIENCES IN THE TREATMENT OF URINARY TRACT INFECTIONS

Pharmacological Evaluation of Amikacin in Neonates

In Vitro Activity of Netilmicin, Gentamicin, and Amikacin

Protein Synthesis Inhibitors

Health Products Regulatory Authority

Comparative Low-Dose Nephrotoxicities of Gentamicin, Tobramycin, and Amikacin

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and

ONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS

available. and P. aeruginosa resistant to gentamicin by standardized disk testing (1) in the Microbiology Laboratory

Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides and Their Postantibiotic Effects

Assessment of gentamiciminduced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium

IJBCP International Journal of Basic & Clinical Pharmacology

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008

Patients. Excludes paediatrics, neonates.

European Public MRL assessment report (EPMAR)

Introduction to Pharmacokinetics and Pharmacodynamics

Gentamicin, Netilmicin, Dibekacin, and Amikacin Nephrotoxicity and Its Relationship to Tubular Reabsorption in Rabbits

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

Prevention of Pyelonephritis Due to Escherichia coli in Rats with Gentamicin Stored in Kidney Tissue

Cell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017

ANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE

Comparative Activity of Netilmicin, Gentamicin, Amikacin, and Tobramycin Against Pseudomonas aeruginosa and Enterobacteriaceae

Comparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal Infections in Monkeys

1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SELECT NEWS. Florfenicol Monograph: Injectable Therapy for Cattle

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES

RENAL CLEARANCE OF CARPROFEN IN THE ISOLATED PERFUSED RAT KIDNEY

Effect of amikacin, cephalothin, clindamycin and vancomycin on in vitro fibroblast growth

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES THE AMINOGLYCOSIDES:

EXCEDE Sterile Suspension

Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Some Antibacterial Agents Used with Koi (oz refers to weight unless otherwise specified)

Studies on Antibiotic Synergism Against Enterococci

Pharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed

PATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION. and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION

Increased nephrotoxicity of gentamicin in pyelonephritic rats

SUMMARY OF PRODUCT CHARACTERISTICS

Case 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION

Summary of Product Characteristics

Diurnal variation in microfilaremia in cats experimentally infected with larvae of

Speciality: Therapeutics

Effects of Fasting on Temporal Variations in Nephrotoxicity of Gentamicin in Rats

Antibiotic Susceptibility of Pseudomonas aeruginosa

Pharmacology Week 6 ANTIMICROBIAL AGENTS

Animal models and PK/PD. Examples with selected antibiotics

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

SELECT NEWS. Florfenicol Monograph: Injectable & Oral Therapy for Swine

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد

Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

Effectiveness and Toxicity of Gentamicin in an Experimental Model of Pyelonephritis: Effect of the Time of Administration

Prospective Comparative Study of Efficacy and Toxicity of Netilmicin and Amikacin

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Burn Infection & Laboratory Diagnosis

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.

Appropriate antimicrobial therapy in HAP: What does this mean?

Original Article Levofloxacin and Gentamicin Induced Nephrotoxicity Pak Armed Forces Med J 2015; 65(4): ORIGINAL ARTICLES

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep

The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens

BIOLACTAM. Product Description. An innovative in vitro diagnostic for the rapid quantitative determination of ß-lactamase activity

Emergence of Gentamicin- and Carbenicillin-Resistant Pseudomonas aeruginosa in a Hospital Environment

OBSERVATIONS ON THE QUALITATIVE AND QUANTITATIVE STRUCTURAL CHARACTERISTICS OF THE REPTILIAN KIDNEYS.

Improved Susceptibility Disk Assay Method Employing an

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Approved by the Food Safety Commission on September 30, 2004

Benefit from high intrarenal levels of gentamicin in the treatment of E. coli pyelonephritis

Tobramycin. Received for publication 5 December 1974

International Journal for Pharmaceutical Research Scholars (IJPRS)

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SOME OBSERVATIONS ON PECKING IN PIGEONS

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018

Antimicrobial therapy in critical care

Other Beta - lactam Antibiotics

ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections

SUMMARY OF PRODUCT CHARACTERISTICS

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.

MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX III LABELLING AND PACKAGE LEAFLET

Project Summary. Impact of Feeding Neomycin on the Emergence of Antibiotic Resistance in E. coli O157:H7 and Commensal Organisms

Title: N-Acetylcysteine (NAC) Mediated Modulation of Bacterial Antibiotic

Clinical and Bacteriological Evaluation of Netilmicin in Gram-Negative Infections

SUMMARY OF PRODUCT CHARACTERISTICS

Dynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus

.'URRENT THERAPEUTIC RESEA. VOLUME 66, NUMBER 3, MAY/JuNE 2005

Reducing Infections in Surgical Practice. Fred A Sweet, MD Rockford Spine Center Illinois, USA

MIACIN HIKMA PHARMACEUTICALS

Update on Therapeutic Drug Monitoring - Aminoglycosides. Antimicrobial Stewardship Forum Cardiff Nov. 2nd 2015

Transcription:

ANTIMICRoBIAL AGENTs AND CHUMOTHKRAY, Oct. 1977, P. 474-478 Copyright 0 1977 American Society for Microbiology Vol. 12, No. 4 Printed in U.S.A. Comparison of the Nephrotoxicity of Netilmicin and Gentamicin in Rats RALPH L. BOWMAN,1 FREDRICK J. SILVERBLATT,' AND GEORGE J. KALOYANIDES2* Veterans Administration Hospital,' and Nephrology and Infectious Disease Divisions, University of California at Los Angeles San Ferando Valley Medical Program,' Sepulveda, California 91343 Received for publication 17 March 1977 The nephrotoxicity of netilmicin relative to that of gentamicin was examined in Sprague-Dawley rats. Balance studies were performed on rats injected with netilmicin or gentamicin (50 mg/kg per day for 14 days, 100 mg/kg per day for 8 days, and 150 mg/kg per day for 8 days). Control rats were injected with saline. Both drugs caused a dose-related decrease in urine osmolality and increases in urine volume, water intake, and serum creatinine; however, the magnitude of these changes was significantly less in netilmicin- than in gentamicin-injected rats. Light microscopy of renal tissue revealed less proximal tubular cell necrosis in netilmicin- than in gentamicin-injected rats. There was no significant difference between the renal cortical concentrations of the two drugs. Both drugs stimulated uptake ofp-aminohippurate in rat renal cortical slices to the same degree. The data indicate that netilmicin is less nephrotoxic than gentamicin in rats, that the difference in nephrotoxicity cannot be explained by a difference in drug concentration in the renal cortex, and that the ability of aminoglycosides to stimulate the organic acid transport system of proximal tubular cells does not correlate with their nephrotoxic potential. Renal failure is a well recognized but poorly understood complication of gentamicin therapy. Recognition ofthis problem has stimulated the development of semisynthetic analogs of gentamicin that possess equivalent antimicrobial efficacy along with a higher ratio of therapeutic effect to toxicity. Netilmicin (Schering 20569, Schering Laboratories, Bloomfield, N. J.) is one such semisynthetic analog ofgentamicin (10). Recent reports indicate that the antimicrobial spectrum of netilmicin is not only similar to that of gentamicin but that this agent exhibits antimicrobial activity against many aminoglycoside-resistant strains of gram-negative bacteria (7, 8). Of equal interest is the recent report of Luft et al. (6) that states that netilmicin is less nephrotoxic than gentamicin in rats. In the present study, we examined the effects of three dose schedules of netilmicin and gentamicin on renal function and morphology in rats to further establish the relative nephrotoxicity of these two agents. MATERIALS AND METHODS Balance studies were performed in three groups of female Sprague-Dawley rats initially weighing 180 to 210 g. The rats were placed in individual metabolic cages and permitted free access to tap water and standard rat chow. A minimum of 10 days was allowed for acclimatization before measurements were begun. After 3 days of control measurements of body weight, water intake, urine volume, urine osmolality, solute excretion, and protein excretion, the rats were injected with one of three agents. In group I, rats received a daily subcutaneous injection of gentamicin sulfate or netilmicin sulfate (40 mg of base per ml) at a dose of 50 mg of base per kg of body weight per day for 14 days. Control rats for each group were injected with an equivalent volume of 0.9% saline (1.25 ml/kg of body weight per day). In group II, rats were injected with drugs at the same concentration but at a dose of 100 mg/kg of body weight per day for 8 days. In group Im, the dose was increased to 150 mg/kg of body weight per day for 8 days. At the end of the study, the rats were sacrificed and the combined weight of both kidneys from each rat was determined. Blood was collected from the aorta and analyzed for urea nitrogen (BUN) and serum creatinine with a Technicon autoanalyzer. Urine was collected under oil, the daily volume was measured, and a portion was analyzed for solute concentration with a Precision osmometer. Urine protein was precipitated with 11% trichloroacetic acid and quantitated by the Lowry method (4). In a separate group of experiments, rats were injected with gentamicin or netilmicin at the same doses and for the same durations as described above. At the end of the experiment, the kidneys were fixed by in vivo perfusion of the renal arteries (3) with 3% glutaraldehyde buffered to ph 7.4 with 0.1 M sodium phosphate. Immediately thereafter, the kidneys were removed and placed in 3% glutaraldehyde for 4 h and then placed in a solution of 0.1 M cacodylate 474

VOL. 12, 1977 with 7% sucrose (ph. 7.4). Subsequently, 1-mm blocks of cortex were embedded in Epon, and 1-,umthick sections were cut and stained with toluidine blue. The sections were coded and examined by blind study under light microscopy for evidence of tubular necrosis and lysosomal changes. In a fourth group of experiments, rats were injected with gentamicin or netilmicin at a dose of 100 mg/kg of body weight per day for 2, 4, and 8 days. Twenty-four hours after the last injection, the rats were sacrificed, and the drug concentration in the renal cortex and medulla was measured by a microbiological assay technique (5). Bacillus globigii was used as the marker organism. The renal cortex and medulla from each rat were dissected, weighed, homogenized, and diluted as necessary with phosphate buffer (ph 8). Antibiotic standards were prepared with the same buffer. In a fifth group of experiments, the effect of gentamicin and netilmicin on p-aminohippurate (PAH) uptake by renal-cortical slices was examined. Rats were injected with drugs at a dose of 100 mg/kg per day for 2 days. Twenty-four hours after the last injection, the kidneys were removed and sliced with a Stadie-Riggs microtome. Cortical slices were incubated for 120 min in a medium containing 10-4 M PAH, after which the concentration ratio of cortical slice to medium PAH was determined as previously described (1). The data in the text and figures are expressed as the mean + standard error. Analysis of variance was used to compare the effects of drug treatment within and between groups. RESULTS Table 1 summarizes the balance data for the control period (day 0) and the last day of treatment for the three-dose schedules of each drug. The first sign of gentamicin or netilmicin nephrotoxicity was a decrease in urine osmolality followed by a rise in urine volume and water intake with no consistent changes in solute excretion. At 50 mg/kg per day, the changes in these variables were similar in gentamicin- and netilmicin-injected rats. At 100 and 150 mg/kg per day, they became more pronounced. However, compared with gentamicin-injected rats, netilmicin-injected rats exhibited significantly greater weight gain (P < 0.01), less depression of urine osmolality (P < 0.01), and no change in solute excretion during both higher dose schedules. Urinary protein excretion increased similarly in response to gentamicin or netilmicin. Figure 1 summarizes the changes in BUN, serum creatinine, and kidney weight in experimental groups I, II, and III. At 50 mg/kg, no difference in BUN was evident among the three groups, but serum creatinine significantly increased in gentamicin (0.64 ± 0.09 mg/100 ml)- and netilmicin-injected rats (0.52 + 0.02 mg/100 ml) compared with that in the saline control rats (0.38 + 0.01 mg/100 ml, P < 0.01). In rats NETILMICIN AND GENTAMICIN NEPHROTOXICITY 475 injected with gentamicin at 100 and 150 mg/kg, BUN and serum creatinine increased sharply and significantly (P < 0.01) above the levels observed in netilmicin- and saline-injected rats. In contrast, at each dose schedule, no difference in BUN was observed between netilmicin- and saline-injected rats (P > 0.1). Although serum creatinine increased slightly in the netilmicin group as a function of drug dose, the increase was impressively less than that observed in gentamicin-injected rats. At 150 mg/kg, serum creatinine increased to 0.84 ± 0.02 mg/100 ml in netilmicin-injected rats as compared with 4.19 + 0.45 mg/100 ml in gentamicin-injected rats (P < 0.01). Kidney weight was significantly greater in gentamicin- and netilmicin-injected rats than in saline-injected rats (P < 0.01). At 100 and 150 mg/kg, kidney weight of gentamicin-injected rats exceeded that of rats injected with netilmicin (P < 0.01). Expressing kidney weight as a function of body weight did not reveal any correlation between kidney weight, drug dosage, BUN, or serum creatinine. The increase in kidney weight most likely indicates interstitial edema reflecting drug-induced, tubular injury. Light microscopic examination of renal tissue revealed dose-related injury characterized by increased lysosomal bodies, disruption of brush borders, cellular swelling, and frank necrosis of proximal tubular epithelium. The changes observed in renal tissue of netilmicininjected rats were less severe than those found in renal tissue of gentamicin-injected rats. The concentration of gentamicin or netilmicin in the renal cortex and medulla was measured after administration of 100 mg/kg per day for 2, 4, and 8 days. In all experiments, the cortical concentrations of the drugs exceeded that of the medulla (P < 0.01). After 2 days of injections, the cortical concentrations of gentamicin and netilmicin were similar (1,029 + 114 and 1,067 + 124 umg/g of cortex, respectively; P > 0.4) and increased to the same extent (2,230 ± 275 and 2,142 + 222,ug/g of cortex, respectively; P > 0.4) after 4 days of injections. After 8 days of injections, netilmicin measured 1,705 ± 151,ug/g of cortex, whereas gentamicin decreased to 832 + 108,ug/g of cortex, P < 0.01. The decrease in the cortical concentration of gentamicin most likely reflects the extensive proximal tubular cell necrosis observed in this group of rats. Both drugs similarly stimulated the uptake of PAH in renal cortical slices. The concentration ratios of cortical slice to medium PAH measured 18.3 + 1.3 and 18.1 + 1.4 in gentamicin- and netilmicin-injected rats, respectively,

476 BOWMAN, SILVERBLATT, AND KALOYANIDES ANTIMICROB. AGENTS CHEMOTHER. x Go z & eqn'to _ +1 +1t+1 +1 +1 +1 +1 tt +1 0 t- co t -4 La 0i kq m N Noc0 V- c_ 3 eq "-" m co tl +I tl Li t e 7& C _- +1 +1 +1 eq goi eq - eq +l +1 +1 1tc_~ r- L. ':LI 4-. 10- hi Go ~bo O N4 C:l N1 _- Nq _- _4 _- C-3 ce +1 +1 +1 +1 +1 +1 +1 +1 +1 gt t- tl tl tl tl tl tl tl tl 0 0 0GNoeqcv Cl N -to4 --r14 r4 I.q. q. 7- r4 ZS C-4 tltll tli 4- -- - - -4 I-q - - c'm eq V-4V4 C5 C5 N; +1 +1+1 +1 +1+1 - - - O O - eqeq"eq o CX - Go 00 wx.q La t.) -9 o co - & -4 C - o X +1 +1+1 +1 +1+1 +1 +1+1 +1 tt +1 +1 +1 +1 +1 +1 +l Z 4) *g >. o & E ; la uzeo;a *,6 a 4) t *mm a: Ss 28 tōb0 0 0 N, q Ss U-) CD cqn 4 N q eq _ 0E- 4 an qq_ 0D kal L01 '.4 '. 4 V-'4,4V-, c,-i,. C +1 +1 +1 +1 +1+1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1 +1 t M o0 00 C C C 0 NM tlot CD Oar- al 0 0 Oo - C3M ~o no M V4V4- o 0a OH oh 4 o C o 6t:0 O o t tl C-4 a +1 +1 eq eq eq c'cq +1 +1 +1 eq M eq& +1 +1+1 +1+1 +1 eqeqem q eqe Iq~ +1 +1+1 +1+1 +1 I" -O) v-0 -- eq " r-4 Mmm =mm =amomo S~~~~~~~~~ St eq it.. r-4 I 0, t- _1. lq o1 _1 _1 _ C _ - OC m o) 4 _ 00 eq eqeq4 t- 6 eq- CQ" I" Ci +1 +1+1 +1 +1 +1 _- m CD m CD m NI% _4 N CD CD CD6 O Obmmcn O O CD Z en Z z j ex j tv 44 +I S s 9 to t ;a g.0 co s e> S e e X s Si st =

VOL. 12, 1977 2001 BUN 1501 mg/loom) 00], 50j a SAL/NE * GENTAMICIN o NErILM/C/N *t NETILMICIN AND GENTAMICIN NEPHROTOXICITY ftt extent as a function of drug dose than that observed in gentamicin-injected rats. (6) also found that netilmicin was Luft et al. less nephrotoxic than gentamicin in Sprague- Dawley rats. These investigators observed a similar pattern of change in urine osmolality 5- and urine volume. In contrast to our study, 4- SCr however, Luft et al. (6) observed a greater increase in proteinuria in gentamicin- than in 3- mg/loo ml 2- netilmicin-injected rats. Moreover, they found >->- - - - - - F - t - - - 0- no significant change in creatinine clearance in rats injected with 30 to 120 mg of netilmicin per 2.5 - - - - Z a~l-- kg per day for 15 days, although histological K.WT 2.0- evidence of tubular 9 injury was present. i.5- In our study, creatinine clearance was not.0 - measured. However, the rise in serum creati- 50 mg/kg 00 mg/kg 150 mg/kg nine from 0.52 to 0.84 mg/100 ml in netilmicin- (14) (8) (8) injected rats (50 and 150 mg/kg, respectively) DOSE PER DAY would suggest that creatinine clearance was (DAYS) depressed. To what extent the rise in serum FIG. 1. Changes in BUN, serum creatiinine (SC.), creatinine reflects a decrease in glomerular filon of drug tration rate secondary to nephron loss or a pos- and kidney weight (K.WT.) as a functiu dose. Symbols: *, significantly different injected rats (P < 0.01); t, significantlrom saline- sible decrease in extracellular volume conse- Fy different from netilmicin-injected rats (P < 0.01). quent to decreased food and water intake remains uncertain. Despite these obvious differences between and were significantly higher than t] hat of the the results of our study and those of Luft et al. saline-injected rats (10.5 ± 0.6, P < C).01). (6), the main conclusion of both is the same, i.e., netilmicin is less nephrotoxic than gentamicin in rats. DISCUSSION The objective of the present studiy was to The mechanism by which aminoglycoside annicin with tibiotics induce renal tubular injury remains compare the nephrotoxicity of netilr that of gentamicin. Both drugs causedi a similar unknown. Several studies have suggested that pattern of nephrotoxicity characterized by a de- nephrotoxicity appears to correlate with the crease in urine osmolality and an iricrease in renal cortical concentration of the drug (2, 5). urine volume, protein excretion, and swrum cre- In the present study, however, we found no atinine. At 50 mg/kg of body weight p)er day for difference in the renal cortical or medullary 14 days, the changes in these parameaters were concentrations of netilmicin and gentamicin similar in gentamicin- and netilmici n-injected after 2 and 4 days of injections at 100 mg/kg per rats. However, at 100 and 150 mg/k;g of body day. After 8 days of injections, the cortical con- of renal centration of gentamicin was significantly less weight per day for 8 days, the severitty impairment caused by netilmicin wfas signifi- than that of netilmicin. These observations are cantly less than that seen in genttamicin-in- evidence against tissue concentration of the jected rats. This conclusion is clearliy evident drugs as the primary explanation for the differfrom comparison of the changes in BUN and ence in nephrotoxic potential of netilmicin and serum creatinine induced by each Iagent. In- gentamicin. creasing the dose of gentamicin fromi 50 to 150 In a previous study, we reported that gentaa progres- micin stimulated renal PAH transport in vivo mg/kg per day was associated with; sive rise in BUN and serum creatinine, and in vitro (1). No effect on PAH transport was whereas identical doses of netilmiciin had no seen with streptomycin (9). These observations significant effect on BUN, and the xrise in se- led us to consider the possibility that stimulathan that tion of the organic acid transport system of rum creatinine was strikingly less seen in gentamicin-injected rats. Mor.eover, ex- renal proximal tubular cells might correlate amination of renal tissue by light naicroscopy with the nephrotoxic potential of aminoglyco- is side antibiotics. This hypothesis is no longer also supports the conclusion that neltilmicin less nephrotoxic than gentamicin. Ti ibular ne- tenable in view of the finding that netilmicin crosis was less severe and progressed to a lesser stimulated PAH uptake to the same extent as 477

478 BOWMAN, SILVERBLAIT, AND KALOYA gentamicin, despite the demonstrated lower nephrotoxicity of this agent. ACKNOWLEDGMENTS This work was supported by the Medical Research Service of the Veterans Administration, by Public Health Service grant HL-19137 from the Heart and Lung Institute, and by a grant from the Schering Corporation. LITERATURE CITED 1. Cohen, L., R. Lapkin, and G. J. Kaloyanides. 1975. Effect of gentamicin on renal function in the rat. J. Pharmacol. Exp. Ther. 193:264-273. 2. Dellinger, P., T. Murphy, M. Barza, V. Pinn, and L. Weinstein. 1976. Effect of cephalothin on renal cortical concentrations of gentamicin in rats. Antimicrob. Agents Chemother. 9:587-588. 3. Griffith, L. D., R. S. Bulger, and B. F. Trump. 1967. The ultrastructure of the functioning kidney. Lab. Invest. 16:220-246. 4. Lowry, 0. H., N. J. Rosebrough, A. L. Farr, and R. J. ANTIMICROB. AGENTS CHEMOTHER. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275. 5. Luft, F. C., V. Patel, M. N. Yum, B. Patel, and S. A. Kleit. 1975. Experimental aminoglycoside nephrotoxicity. J. Lab. Clin. Med. 86:213-220. 6. Luft, F. C., M. N. Yum, and S. A. Kleit. 1976. Comparative nephrotoxicities of netilmicin and gentamicin in rats. Antimicrob. Agents Chemother. 10:845-849. 7. Miller, G. H., G. Arcieri, M. J. Weinstein, and J. A. Waitz. 1976. Biological activity of netilmicin, a broad-spectrum semisynthetic aminoglycoside antibiotic. Antimicrob. Agents Chemother. 10:827-836. 8. Rahal, J. J., Jr., M. S. Semberkoff, K. Kagan, and N. H. Moldover. 1976. Bactericidal efficacy of Sch 20569 and amikacin against gentamicin-sensitive and -resistant organisms. Antimicrob. Agents Chemother. 9:595-599. 9. Wilson, R., H. Enser, R. Lapkin, and G. J. Kaloyanides. 1974. The effect of aminoglycoside antibiotics on PAH uptake by rat kidney slices. Clin. Res. 22:627A. 10. Wright, J. J. 1975. Synthesis of 1-N-ethyl-sisomicin: a broad-spectrum semi-synthetic aminoglycoside antibiotic. J. Chem. Soc. Chem. Commun. 6:206-208. Downloaded from http://aac.asm.org/ on November 22, 2018 by guest